Previous 10 | Next 10 |
2024-01-25 15:30:27 ET Summary Vera Therapeutics, Inc. stock price soared over 35% today as it announced positive results from the open label extension of its Phase 2b ORIGIN clinical trial for atacicept in IgA nephropathy. The company's stock is up over 160% in the past year and ...
2024-01-14 12:00:24 ET More on CRISPR, GSK, etc. Pfizer Is Part Of The 2024 Healthcare Sector Rally Cohort Impact Of Gene Therapies And Casgevy On Crispr AG And The Industry CRISPR Therapeutics AG (CRSP) 42nd Annual J.P. Morgan Healthcare Conference (Transcript) ...
Calliditas Therapeutics provides business update ahead of JP Morgan conference PR Newswire STOCKHOLM , Jan. 8, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) (STO: CALTX) ("Calliditas"), a commercial biopharma company focused on rare disease...
Calliditas Therapeutics appoints Maria Törnsén as President North America PR Newswire STOCKHOLM , Jan. 7, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas"), a commercial biopharma company focus...
Calliditas to present at JP Morgan Healthcare Conference PR Newswire STOCKHOLM , Jan. 7, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced that management will present at and participate in the...
2023-12-27 13:25:53 ET Calliditas Therapeutics ( NASDAQ: CALT ) said Friday it has signed and fully drawn a term loan of 92 million Euros with funds managed by Athyrium Capital Management LP. Proceeds from the loan will primarily be utilized for full repayment of the company's e...
Calliditas refinances existing term loan with Euro 92 million senior secured facility with Athyrium Capital PR Newswire STOCKHOLM , Dec. 27, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) and (Nasdaq Stockholm: CALTX) ("Calliditas") today an...
2023-12-21 11:11:40 ET More on Calliditas Therapeutics Calliditas Therapeutics: Undervalued Rare Disease Commercial Stage Biotech (Maintaining Buy) Calliditas partner wins China nod for kidney disease therapy Calliditas stock dips as losses widen in Q3 Seekin...
2023-12-21 10:08:45 ET U.S. stocks on Thursday gained , with markets rebounding from their worst sell-off since late September. Wall Street in the previous session slid more than 1% after a seven-week bull run, in a decline that was chalked up to overbought territory and zero-day option...
2023-12-21 08:33:51 ET Infrared Cameras Holdings ( MSAI ) +140% . Shengfeng Development ( SFWL ) +40% . Annexon ( ANNX ) +39% stock jumps on pricing of $125M public offering of common stock. ParaZero Technologies ( PRZO ) +33% ...
News, Short Squeeze, Breakout and More Instantly...
Calliditas Therapeutics AB Company Name:
CALT Stock Symbol:
NASDAQ Market:
Calliditas partner STADA receives European Commission decision for full approval of Kinpeygo® for the treatment of IgA Nephropathy PR Newswire STOCKHOLM , July 26, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Ca...
Calliditas announces positive TRANSFORM Phase 2b topline data in primary biliary cholangitis PR Newswire STOCKHOLM , July 26, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) ( STOCKHOLM : CALTX) ("Calliditas") today announced that the Pha...
Launch of Phase 3 clinical trial with Nefecon in Japan PR Newswire STOCKHOLM , July 4, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) (STO: CALTX) ("Calliditas") today announces that its partner Viatris Pharmaceutical Japan G.K. ("Viatri...